 The Company will host a conference call at 8:30 am Eastern Time to discuss the results and provide a corporate update. A live audio webcast of the presentation will be available via the Investor Relations page of the Entera Bio website, or by clicking here. A replay of the webcast will be archived on Entera website for approximately 45 days following the call. Entera Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in orphan indications and other areas with significant unmet medical needs. The Company is initially applying its technology to develop an oral formulation of a human parathyroid hormone analog, Oral PTH 1-34, for treatment of hypoparathyroidism and osteoporosis. 